BriaCell Therapeutics’ (BCTX) Buy Rating Reiterated at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $18.00 price objective on the stock.

BriaCell Therapeutics Stock Down 4.7 %

BCTX stock opened at $1.43 on Friday. BriaCell Therapeutics has a 52-week low of $1.30 and a 52-week high of $7.59. The stock’s 50 day moving average is $2.32 and its two-hundred day moving average is $3.54. The company has a market capitalization of $22.85 million, a PE ratio of -0.85 and a beta of 1.14.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.51). As a group, sell-side analysts anticipate that BriaCell Therapeutics will post -1.39 EPS for the current year.

Institutional Investors Weigh In On BriaCell Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Onyx Bridge Wealth Group LLC increased its holdings in shares of BriaCell Therapeutics by 66.7% in the 1st quarter. Onyx Bridge Wealth Group LLC now owns 50,000 shares of the company’s stock valued at $143,000 after acquiring an additional 20,000 shares during the last quarter. K.J. Harrison & Partners Inc grew its stake in BriaCell Therapeutics by 7.8% during the 1st quarter. K.J. Harrison & Partners Inc now owns 87,044 shares of the company’s stock worth $249,000 after buying an additional 6,329 shares during the last quarter. National Bank of Canada FI grew its stake in BriaCell Therapeutics by 200.0% during the 4th quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock worth $40,000 after buying an additional 5,000 shares during the last quarter. Finally, K2 Principal Fund L.P. bought a new position in BriaCell Therapeutics during the 3rd quarter worth $156,000. 15.42% of the stock is currently owned by institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.